Table 2.

Characteristics of oral methotrexate prior to subcutaneous methotrexate treatment and subcutaneous methotrexate utilization in UMAR study

Characteristics		Missing (n)
Oral methotrexate
Duration, months (mean ± SD)	55.84 ± 53.32	3
Mean dose (mean ± SD)	14.31 ± 0.46
Reason for treatment discontinuation [n (%)]		4
Adverse events	13 (28.26)
Lack of efficacy	32 (69.57)
Adverse events and other	1 (2.17)
Subcutaneous methotrexate
Mean dose, mg (mean ± SD)	18.36 ± 0.53
Dose, mg [n (%)]; mean duration (months)
8	1 (2.00); 3.68
10	11 (22.00); 14.72
15	24 (48.00); 17.02
20	31 (62.00); 15.63
25	12 (24.00); 24.08
Reason for treatment discontinuation [n (%)]
Adverse events	6 (66.67)
Lack of efficacy	2 (22.22)
Other	1 (11.11)

The sum differs (9 = 100%) since one participant discontinued the treatment due to more than one reason

SD standard deviation, UMAR Utilization of Metoject^® in Rheumatoid Arthritis